

Christian E Badr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5847524/publications.pdf>

Version: 2024-02-01

37
papers

1,716
citations

430874

18
h-index

477307

29
g-index

41
all docs

41
docs citations

41
times ranked

6021
citing authors

#	ARTICLE	IF	CITATIONS
1	Orthotopic brain tumor models derived from glioblastoma stem-like cells. <i>Methods in Cell Biology</i> , 2022, , .	1.1	1
2	Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. <i>Biochemical Pharmacology</i> , 2021, 183, 114317.	4.4	13
3	Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models. <i>STAR Protocols</i> , 2021, 2, 100290.	1.2	2
4	DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i8-i8.	0.7	0
5	DDRE-05. STEAROYL COA DESATURASE IS ESSENTIAL FOR REGULATION OF ENDOPLASMIC RETICULUM HOMEOSTASIS AND TUMOR GROWTH IN GLIOBLASTOMA CANCER STEM CELLS. <i>Neuro-Oncology Advances</i> , 2021, 3, i7-i7.	0.7	0
6	Multiplexed bioluminescence-mediated tracking of DNA double-strand break repairs in vitro and in vivo. <i>Nature Protocols</i> , 2021, 16, 3933-3953.	12.0	6
7	EXTH-23. PRECLINICAL EFFICACY OF A TARGETED, BRAIN PENETRANT INHIBITOR OF FATTY ACID DESATURATION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi168-vi168.	1.2	0
8	A multiplexed bioluminescent reporter for sensitive and non-invasive tracking of DNA double strand break repair dynamics in vitro and in vivo. <i>Nucleic Acids Research</i> , 2020, 48, e100-e100.	14.5	10
9	Metabolic heterogeneity and adaptability in brain tumors. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 5101-5119.	5.4	34
10	Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. <i>ACS Chemical Biology</i> , 2020, 15, 1445-1454.	3.4	18
11	An allosteric inhibitor of SHP2 effectively targets PDGFR \pm -driven glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1348-1349.	1.2	4
12	A TNF-NF- κ B-STAT3 loop triggers resistance of glioma-stem-like cells to Smac mimetics while sensitizing to EZH2 inhibitors. <i>Cell Death and Disease</i> , 2019, 10, 268.	6.3	8
13	Sustained NF- κ B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. <i>Cell Death Discovery</i> , 2019, 5, 72.	4.7	18
14	Stearoyl CoA Desaturase Is Essential for Regulation of Endoplasmic Reticulum Homeostasis and Tumor Growth in Glioblastoma Cancer Stem Cells. <i>Stem Cell Reports</i> , 2019, 12, 712-727.	4.8	62
15	Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery. <i>Journal of Neuro-Oncology</i> , 2018, 139, 293-305.	2.9	24
16	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	1.2	35
17	STEM-16. TARGETING THE SCF UBIQUITIN LIGASE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi229-vi229.	1.2	0
18	Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16017.	4.4	21

#	ARTICLE	IF	CITATIONS
19	Intracranial AAV Δ TRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. <i>Molecular Oncology</i> , 2016, 10, 625-634.	4.6	18
20	STEM-18 CULTURE CONDITION-INDUCED MESENCHYMAL TRANSITION IN PATIENT-DERIVED GLIOBLASTOMA STEM CELLS. <i>Neuro-Oncology</i> , 2015, 17, v211.5-v212.	1.2	0
21	Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. <i>Nature Communications</i> , 2015, 6, 7029.	12.8	449
22	Bioluminescence Imaging: Basics and Practical Limitations. <i>Methods in Molecular Biology</i> , 2014, 1098, 1-18.	0.9	48
23	Systemic Anticancer Neural Stem Cells in Combination with a Cardiac Glycoside for Glioblastoma Therapy. <i>Stem Cells</i> , 2014, 32, 2021-2032.	3.2	18
24	Cell-Based Bioluminescence Screening Assays. <i>Methods in Molecular Biology</i> , 2014, 1098, 185-195.	0.9	1
25	Triple Bioluminescence Imaging for In Vivo Monitoring of Cellular Processes. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e99.	5.1	77
26	Targeting Cancer Cells With the Natural Compound Obtusaquinone. <i>Journal of the National Cancer Institute</i> , 2013, 105, 643-653.	6.3	19
27	Abstract A254: Systemic injection of human neural stem cells expressing anti-cancer agent targets invasive gliomas and induces tumor regression in combination with a cardiac glycoside.. , 2013, , .		0
28	Bioluminescence imaging: progress and applications. <i>Trends in Biotechnology</i> , 2011, 29, 624-633.	9.3	240
29	Functional Drug Screening Assay Reveals Potential Glioma Therapeutics. <i>Assay and Drug Development Technologies</i> , 2011, 9, 281-289.	1.2	31
30	Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor α -related apoptosis-inducing ligand and induces an alternative cell death pathway. <i>Neuro-Oncology</i> , 2011, 13, 1213-1224.	1.2	52
31	Suicidal gene therapy in an NF- κ B-controlled tumor environment as monitored by a secreted blood reporter. <i>Gene Therapy</i> , 2011, 18, 445-451.	4.5	15
32	Real-Time Monitoring of Nuclear Factor κ B Activity in Cultured Cells and in Animal Models. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00026.	1.4	56
33	Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. <i>Molecular Imaging</i> , 2009, 8, 278-90.	1.4	49
34	A secreted luciferase for ex vivo monitoring of in vivo processes. <i>Nature Methods</i> , 2008, 5, 171-173.	19.0	263
35	A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress. <i>PLoS ONE</i> , 2007, 2, e571.	2.5	123
36	956. Imaging of Radiation-Inducible Promoters Using a Naturally Secreted Luciferase from the Marine Copepod <i>Gaussia princeps</i> . <i>Molecular Therapy</i> , 2006, 13, S369.	8.2	0

#	ARTICLE	IF	CITATIONS
37	Gaussia luciferase blood level as an index of cell growth and proliferation. Protocol Exchange, 0, , .	0.3	1